Trial Profile
A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afamelanotide (Primary)
- Indications Erythropoietic protoporphyria
- Focus Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 17 Apr 2014 New trial record